RU2005100781A - Комбинация азеластина и стероидов - Google Patents
Комбинация азеластина и стероидов Download PDFInfo
- Publication number
- RU2005100781A RU2005100781A RU2005100781/15A RU2005100781A RU2005100781A RU 2005100781 A RU2005100781 A RU 2005100781A RU 2005100781/15 A RU2005100781/15 A RU 2005100781/15A RU 2005100781 A RU2005100781 A RU 2005100781A RU 2005100781 A RU2005100781 A RU 2005100781A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- pharmaceutically acceptable
- azelastine
- composition
- steroid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (25)
1. Фармацевтическая композиция, которая содержит азеластин или его фармацевтически приемлемую соль, сольват или физиологически функциональное производное и стероид или его фармацевтически приемлемую соль, сольват или физиологически функциональное производное, причем композиция предпочтительно представлена в форме, подходящей для введения в нос или глаза, и необязательно содержит носитель или наполнитель.
2. Фармацевтическая композиция по п.1, где указанный азеластин присутствует в виде гидрохлорида азеластина.
3. Композиция по п.2, где стероидом является беклометазон или его фармацевтически приемлемый сложный эфир, мометазон или его фармацевтически приемлемый сложный эфир, флутиказон или его фармацевтически приемлемый сложный эфир, будезонид или циклозенид, в любой хиральной форме или смеси.
4. Композиция по п.3, где стероидом является пропионат беклометазона, фуроат мометазона, моногидрат фуроата мометазона, пропионат флутиказона или валерат флутиказона.
5. Композиция по п.1, которая содержит стероид в количестве примерно от 50 мкг/мл и примерно до 5 мг/мл композиции.
6. Композиция по п.1, имеющая размер частиц менее чем примерно 10 мкм, предпочтительно менее чем 5 мкм.
7. Композиция по п.1, которая представляет собой суспензию, содержащую от 0,0005 до 2% (мас./мас. композиции) азеластина или фармацевтически приемлемой соли азеластина и от 0,5 до 1,5% (мас./мас. композиции) указанного стероида.
8. Композиция по п.7, которая содержит от 0,001 до 1% (мас./мас. композиции) азеластина или его соли и от 0,5 до 1,5% (мас./мас. композиции) стероида.
9. Композиция по п.1, которая дополнительно содержит поверхностно-активное вещество, содержащее полисорбатное или полоксамерное поверхностно-активное вещество.
10. Композиция по п.9, которая содержит примерно от 50 мкг и примерно до 1 мг поверхностно-активного вещества на мл композиции.
11. Композиция по п.1, которая дополнительно содержит изотонический агент, содержащий хлорид натрия, сахарозу, глюкозу, глицерин, сорбит или 1,2-пропиленгликоль.
12. Композиция по п.1, которая дополнительно содержит по меньшей мере один из следующих компонентов: буфер, консервант и суспендирующий или сгущающий агент; при этом указанный консервант выбран из эдетовой кислоты и ее щелочных солей, (низший алкил) - п-гидроксибензоатов, хлоргексидина, бората фенилртути или бензойной кислоты или соли, соединения четвертичного аммония или сорбиновой кислоты или ее соли, причем суспендирующий агент или сгущающий агент выбран из производных целлюлозы, желатина, поливинилпирролидона, трагаканта, этоксозы (водорастворимых вяжущих и сгущающих агентов на основе этилцеллюлозы), альгиновой кислоты, поливинилового спирта, полиакриловой кислоты или пектина, а буфер содержит буфер цитрат-лимонная кислота.
13. Композиция по п.1, где буфер поддерживает рН водной фазы на уровне от 3 до 7, предпочтительно от 4,5 примерно до 6,5.
14. Фармацевтическая композиция по п.1, которая содержит гидрохлорид азеластина и дипропионат беклометазона, вместе с их фармацевтически приемлемым носителем или разбавителем.
15. Фармацевтическая композиция по п.1, которая содержит гидрохлорид азеластина и дипропионат флутиказона, вместе с их фармацевтически приемлемым носителем или разбавителем.
16. Фармацевтическая композиция по п.1, которая содержит гидрохлорид азеластина и валерат флутиказона, вместе с их фармацевтически приемлемым носителем или разбавителем.
17. Фармацевтическая композиция по п.1, которая содержит гидрохлорид азеластина и фуроат мометазона или моногидрат мометазона, вместе с их фармацевтически приемлемым носителем или разбавителем.
18. Композиция по любому из предшествующих пунктов, которая представлена в виде водной суспензии или раствора.
19. Композиция по п.18, которая представлена в виде аэрозоля, мази, глазных капель, капель в нос, назального спрея или раствора для ингаляции.
20. Композиция по п.19, которая представлена в виде капель в нос или назального спрея.
21. Композиция по п.19 или 20, которая представлена в виде аэрозоля.
22. Композиция по любому из пп.1-17, которая представлена в виде инсуффляционного порошка.
23. Способ профилактики или лечения у млекопитающего, такого как человек, состояний, при которых показано введение одного или более антигистаминных средств и/или одного или более стероидных средств, причем указанный способ включает в себя введение терапевтически эффективного количества фармацевтической композиции по любому из пп.1-17.
24. Способ по п.23, предназначенный для лечения раздражения или расстройств носа или глаза, который включает в себя нанесение, в случае необходимости, указанной композиции либо непосредственно в ткани носа, либо в конъюнктивальный мешок глаза.
25. Способ по п.23, предназначенный для лечения расстройств дыхательных путей, который включает в себя введение путем распыления на поверхностях дыхательных путей эффективного для лечения количества указанной композиции.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0213739.6 | 2002-06-14 | ||
GB0213739A GB2389530B (en) | 2002-06-14 | 2002-06-14 | Pharmaceutical compositions |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2005100781A true RU2005100781A (ru) | 2005-08-10 |
RU2361593C2 RU2361593C2 (ru) | 2009-07-20 |
RU2361593C3 RU2361593C3 (ru) | 2022-04-04 |
Family
ID=9938620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005100781A RU2361593C3 (ru) | 2002-06-14 | 2003-06-13 | Комбинация азеластина и стероидов |
Country Status (29)
Country | Link |
---|---|
US (10) | US8168620B2 (ru) |
EP (3) | EP1519731B1 (ru) |
KR (3) | KR101301558B1 (ru) |
CN (1) | CN1674910A (ru) |
AP (1) | AP2004003192A0 (ru) |
AT (1) | ATE428428T1 (ru) |
AU (3) | AU2003244799B2 (ru) |
BR (1) | BRPI0312128B8 (ru) |
CA (3) | CA2779633C (ru) |
CR (1) | CR7654A (ru) |
CY (4) | CY1109196T1 (ru) |
DE (1) | DE60327203D1 (ru) |
DK (3) | DK2075000T3 (ru) |
ES (3) | ES2545205T3 (ru) |
GB (1) | GB2389530B (ru) |
GE (1) | GEP20115143B (ru) |
HU (2) | HUE027184T2 (ru) |
IL (3) | IL165771A (ru) |
LU (1) | LU92269I2 (ru) |
MA (1) | MA27285A1 (ru) |
MX (1) | MXPA04012666A (ru) |
NZ (2) | NZ574658A (ru) |
PL (1) | PL373001A1 (ru) |
PT (3) | PT1519731E (ru) |
RU (1) | RU2361593C3 (ru) |
SI (3) | SI1519731T1 (ru) |
TN (1) | TNSN04247A1 (ru) |
WO (1) | WO2003105856A1 (ru) |
ZA (1) | ZA200500331B (ru) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
PT1545548E (pt) | 2002-08-30 | 2010-09-02 | Nycomed Gmbh | Utilização da combinação de ciclesonida e anti-histamínicos para o tratamento de rinite alérgica |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US8758816B2 (en) * | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
US20070020330A1 (en) * | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
DK2486942T3 (en) | 2004-11-24 | 2019-01-28 | Meda Pharmaceuticals Inc | COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT |
MX2007011772A (es) | 2005-03-23 | 2007-12-05 | Elan Pharma Int Ltd | Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas. |
US20070202055A1 (en) * | 2006-02-09 | 2007-08-30 | Julianne Berry | Pharmaceutical Formulations |
DE102006034883A1 (de) * | 2006-07-25 | 2008-01-31 | Hermal Kurt Herrmann Gmbh & Co. Ohg | Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
US8865692B2 (en) * | 2007-11-13 | 2014-10-21 | Meritage Pharma, Inc | Compositions for the treatment of gastrointestinal inflammation |
US8569273B2 (en) * | 2009-03-17 | 2013-10-29 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
MX2011009802A (es) | 2009-03-17 | 2011-11-02 | Aciex Therapeutics Inc | Formulaciones oftalmicas de cetirizina y metodos de uso. |
EP2437743A4 (en) * | 2009-06-05 | 2012-11-28 | Aciex Therapeutics Inc | OPHTHALMIC FORMULATIONS OF FLUTICASONE AND METHODS OF USE |
CN102099704B (zh) | 2009-09-28 | 2013-07-03 | 上海奕瑞影像科技有限公司 | 一种x射线图像探测装置 |
WO2011141929A2 (en) | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Aqueous pharmaceutical compositions of fluticasone and olopatadine |
KR101261230B1 (ko) | 2010-11-29 | 2013-05-07 | 한림제약(주) | 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물 |
GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
CN102448496B (zh) * | 2011-06-22 | 2015-04-15 | 江苏德达医药科技有限公司 | 含碘和类固醇的药物组合物及其用于治疗鼻炎疾病的用途 |
KR101304341B1 (ko) * | 2011-09-19 | 2013-09-11 | 한미약품 주식회사 | 코르티코스테로이드, 항히스타민제 및 β-사이클로덱스트린을 포함하는, 안정성이 개선된 약학 조성물 |
GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201117621D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201121812D0 (en) * | 2011-12-07 | 2012-02-01 | Teva Branded Pharmaceutical Prod R & D Inc | NAsal formulation |
WO2013130619A1 (en) * | 2012-02-27 | 2013-09-06 | O-Ray Pharma, Inc. | Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders |
WO2014087347A1 (en) * | 2012-12-06 | 2014-06-12 | Glenmark Pharmaceuticals Limited | Fixed dose pharmaceutical composition comprising mometasone and azelastine |
KR20140081925A (ko) * | 2012-12-12 | 2014-07-02 | 한미약품 주식회사 | 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제 |
JP6545148B2 (ja) | 2013-03-13 | 2019-07-17 | フラットリー ディスカバリー ラブ,エルエルシー | ピリダジノン化合物及び嚢胞性線維症の治療のための方法 |
GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
PL3043773T3 (pl) | 2013-09-13 | 2021-12-13 | Glenmark Specialty S.A. | Stabilna stała dawka kompozycji farmaceutycznej zawierającej mometazon i olopatadynę do podania donosowego |
CN103784462A (zh) * | 2014-02-25 | 2014-05-14 | 宋俊智 | 包含比拉斯汀及甾族化合物的药物制剂 |
US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
EP2985019B1 (en) * | 2014-08-16 | 2021-10-20 | Church & Dwight Co., Inc. | Nasal composition having anti-viral properties |
EP2985027B1 (en) | 2014-08-16 | 2021-03-31 | Church & Dwight Co., Inc. | Nasal composition comprising mixture of hyaluronic acids and saline solution |
CN104173286B (zh) * | 2014-09-10 | 2017-03-01 | 贵州云峰药业有限公司 | 氮卓斯汀组合物和用途 |
CN106806342A (zh) * | 2015-12-01 | 2017-06-09 | 四川海思科制药有限公司 | 一种盐酸氮卓斯汀丙酸氟替卡松鼻喷剂药物组合物及其制备方法 |
BR122020022602B1 (pt) | 2015-12-04 | 2024-03-05 | Mexichem Fluor S.A. De C.V. | Composição farmacêutica |
US20190269703A1 (en) * | 2016-05-17 | 2019-09-05 | Mayo Foundation For Medical Education And Research | Materials and methods for treating chronic cough |
TWI717539B (zh) * | 2017-07-25 | 2021-02-01 | 健喬信元醫藥生技股份有限公司 | 鼻用醫藥組合物及其製備方法及鼻用複方懸浮液 |
CN109288790A (zh) * | 2017-07-25 | 2019-02-01 | 健乔信元医药生技股份有限公司 | 鼻用医药组合物及其制备方法 |
CN107929738A (zh) * | 2017-11-28 | 2018-04-20 | 贵州云峰药业有限公司 | 一种含盐酸氮卓斯汀的组合物 |
CN107737105A (zh) * | 2017-11-28 | 2018-02-27 | 贵州云峰药业有限公司 | 一种鼻腔用盐酸氮卓斯汀组合物喷雾剂及生产工艺 |
WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US20210330584A1 (en) * | 2020-04-22 | 2021-10-28 | Topical Sinus Therapeutics, Inc. | Topical preparations of drug delivery for nasal and sinus irrigation |
CA3183560A1 (en) * | 2020-06-26 | 2021-12-30 | Jianmin Wang | Compositions and methods for treating alzheimer's disease and parkinson's disease |
WO2022098319A1 (en) * | 2020-11-09 | 2022-05-12 | Pharmactive Ilac Sanayi Ve Ticarey A.S. | Pharmaceutical compositions comprising azelastine, beclomethasone and relevant excipients |
WO2022108471A1 (ru) * | 2020-11-20 | 2022-05-27 | Герман Петрович БЕККЕР | Средство для лечения и профилактики острых респираторных вирусных инфекций |
US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
US20230310440A1 (en) * | 2022-04-01 | 2023-10-05 | Enalare Therapeutics Inc. | Respiratory stimulant nasal formulations |
WO2024063712A1 (en) * | 2022-09-20 | 2024-03-28 | Pharmactive Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients |
Family Cites Families (200)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2837464A (en) | 1955-01-11 | 1958-06-03 | Schering Corp | Process for production of dienes by corynebacteria |
DE1059906B (de) | 1954-10-05 | 1959-06-25 | Scherico Ltd | Verfahren zur Herstellung von 1, 4-Pregnadienen |
US3067197A (en) | 1961-04-26 | 1962-12-04 | Pfizer & Co C | 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives |
GB1047518A (en) | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª-monoesters of 11,17,21-trihydroxy steroid compounds |
GB1159490A (en) | 1966-02-09 | 1969-07-23 | Boots Pure Drug Co Ltd | Improvements in Acylated Steroids |
US3639434A (en) | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
IT1061787B (it) | 1967-03-01 | 1983-04-30 | Vismara Francesco Spa | Miglioramenti relativi alla preparazione di 17 benzoato di betametazone |
GB1227992A (ru) | 1968-01-23 | 1971-04-15 | Koninklijke Gist Spiritus | |
IT1034011B (it) | 1969-06-26 | 1979-09-10 | Vister Vismara Terapeutici S P | Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato |
GB1384372A (en) | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
CH572914A5 (ru) | 1971-01-22 | 1976-02-27 | Asta Werke Ag Chem Fab | |
US3813384A (en) | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
US3828080A (en) | 1972-01-20 | 1974-08-06 | Glaxo Lab Ltd | Androstane-17beta-carboxylic acids and processes for the preparation thereof |
US3989686A (en) | 1972-06-15 | 1976-11-02 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstane series and process for preparing same |
GB1438940A (en) | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
GB1440063A (en) | 1972-08-11 | 1976-06-23 | Glaxo Lab Ltd | 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids |
US4093721A (en) | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
GB1517278A (en) | 1974-08-30 | 1978-07-12 | Glaxo Lab Ltd | Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates |
YU54476A (en) | 1975-03-31 | 1982-05-31 | Taisho Pharmaceutical Co Ltd | Process for obtaining 17-ester 21-halo-pregnane |
CH628355A5 (de) | 1976-02-24 | 1982-02-26 | Ciba Geigy Ag | Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze. |
US4221787A (en) | 1978-03-28 | 1980-09-09 | Interx Research Corporation | Esteramide prodrugs of anti-inflammatory corticosteroids |
US4198403A (en) | 1978-04-05 | 1980-04-15 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes |
US4188385A (en) | 1978-04-05 | 1980-02-12 | Syntex (U.S.A.) Inc. | Thioetianic acid derivatives |
US4187301A (en) | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
US4263289A (en) | 1978-04-05 | 1981-04-21 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
US4261984A (en) | 1978-04-05 | 1981-04-14 | Syntex (U.S.A.) Inc. | 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes |
DE2817988A1 (de) | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
US4310466A (en) | 1979-08-31 | 1982-01-12 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
US4267173A (en) | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
ZA81976B (en) | 1980-02-15 | 1982-07-28 | Glaxo Group Ltd | Androstane carbothioates |
GB2088877B (en) | 1980-02-15 | 1984-07-04 | Glaxo Group Ltd | Androstane 17 carbothioates |
US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
US4710495A (en) | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
ZA814440B (en) | 1980-07-10 | 1982-10-27 | Otsuka Pharma Co Ltd | Soft steroids having anti-inflammatory activity |
SE449106B (sv) | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4607028A (en) | 1983-08-18 | 1986-08-19 | Ciba-Geigy Corporation | Novel carboxylic acid esters |
US4552899A (en) | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
EP0179583A1 (en) | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
US4861765A (en) | 1985-06-26 | 1989-08-29 | Jouveinal | 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them |
US4782047A (en) | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
ZA872389B (en) | 1987-04-02 | 1987-11-25 | Advanced Polymer Systems Inc | Composition and method for delivering a steroid active ingredient |
ATE90355T1 (de) | 1987-10-13 | 1993-06-15 | Nicholas S Bodor | Weiche steroide mit anti-entzuendungswirkung. |
US5232919A (en) | 1987-11-13 | 1993-08-03 | Asta Pharma Aktiengesellschaft | Azelastine embonate and compositions which contain it |
DE3836579A1 (de) | 1987-11-13 | 1989-05-24 | Asta Pharma Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge |
EP0316633B1 (de) | 1987-11-13 | 1993-01-27 | ASTA Medica Aktiengesellschaft | Azelastin enthaltende Arzneimittel zur Anwendung in der Nase und/oder am Auge |
US5271946A (en) | 1988-04-20 | 1993-12-21 | Asta Pharma Aktiengesellschaft | Controlled release azelastine-containing pharmaceutical compositions |
US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
FR2644788B1 (fr) | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
US5202316A (en) | 1989-03-22 | 1993-04-13 | Roussel Uclaf | N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines |
JPH07116215B2 (ja) | 1989-04-19 | 1995-12-13 | エスエス製薬株式会社 | 新規なステロイド化合物 |
ATE107643T1 (de) * | 1989-05-05 | 1994-07-15 | Asta Medica Ag | Salze des azelastins mit verbesserter löslichkeit. |
AU5640390A (en) | 1989-06-16 | 1991-01-08 | Upjohn Company, The | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
DE4025342A1 (de) | 1990-08-10 | 1992-02-13 | Hoechst Ag | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
GB9103764D0 (en) | 1991-02-22 | 1991-04-10 | Glaxo Group Ltd | Compositions |
NZ243062A (en) * | 1991-06-10 | 1993-09-27 | Schering Corp | Aerosol containing medicament and 1,1,1,2-tetrafluoroethane |
US6127353A (en) | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
CA2146637C (en) | 1992-10-09 | 2001-02-13 | James Grigg Upson | Pharmaceutical compositions and methods for treating cold symptoms |
FI941777A (fi) | 1993-04-16 | 1994-10-17 | Mcneil Ppc Inc | Vesipitoinen farmaseuttinen suspensio ja menetelmä sen valmistamiseksi |
DE4322703A1 (de) | 1993-07-08 | 1995-01-12 | Asta Medica Ag | Druckgaspackungen unter Verwendung von Polyoxyethylen-glyceryl-fettsäureestern als Suspensionsstabilisatoren und Ventilschmiermittel |
JP4208267B2 (ja) | 1993-07-30 | 2009-01-14 | キヤノン株式会社 | 制御装置 |
DE4328819A1 (de) | 1993-08-27 | 1995-03-02 | Hoechst Ag | Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
DE4333920A1 (de) | 1993-10-05 | 1995-04-13 | Hoechst Ag | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
WO1995013810A1 (en) | 1993-11-19 | 1995-05-26 | Schering-Plough Healthcare Products Incorporated | Nasal spray compositions containing oxymetazoline |
US5576437A (en) | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
US5420120A (en) | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
US5897858A (en) | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
IL109656A (en) | 1994-05-15 | 1998-02-22 | Chemagis Ltd | Process for the manufacture of androstane - 17 - carbothioates and androstane - 17 - carbothioates prepared thereby |
GB9410222D0 (en) | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
GB9419536D0 (en) | 1994-09-28 | 1994-11-16 | Glaxo Inc | Medicaments |
SA95160463B1 (ar) | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | مساحيق للاستنشاق |
DE4446891A1 (de) | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
HU219899B (hu) | 1995-04-14 | 2001-09-28 | Glaxo Wellcome Inc. | Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban |
JPH08291072A (ja) | 1995-04-22 | 1996-11-05 | Kissei Pharmaceut Co Ltd | 吸入用粉末製剤用結晶とその製造方法 |
JPH08291073A (ja) | 1995-04-22 | 1996-11-05 | Kissei Pharmaceut Co Ltd | 医薬品組成物及びその製造方法 |
AU6392496A (en) * | 1995-06-29 | 1997-01-30 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
DE19528145A1 (de) | 1995-08-01 | 1997-02-06 | Boehringer Ingelheim Kg | Neue Arzneimittel und ihre Verwendung |
GB9521696D0 (en) | 1995-10-23 | 1996-01-03 | Bayer Ag | Combination of LTD4 receptor antagonists with glucocorticosteriods |
US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
US5792758A (en) | 1995-12-08 | 1998-08-11 | G. D. Searle & Co. | Steroid nitrite ester derivatives useful as anti-inflammatory drugs |
US5707984A (en) | 1995-12-08 | 1998-01-13 | G. D. Searle & Co. | Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs |
EP0780127A1 (en) * | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
SK89198A3 (en) | 1995-12-29 | 1999-03-12 | Glaxo Group Ltd | Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives |
US6881423B2 (en) | 1996-02-27 | 2005-04-19 | Teijin Limited | Powdery composition for nasal administration |
US5985862A (en) | 1996-05-02 | 1999-11-16 | G.D. Searle & Co. | Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs |
US5981517A (en) | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
EP0954318A1 (en) | 1996-06-04 | 1999-11-10 | The Procter & Gamble Company | A nasal spray containing an intranasal steroid and an antihistamine |
US5976573A (en) | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
GB9622173D0 (en) | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
FR2756739B1 (fr) | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
TW503113B (en) | 1997-01-16 | 2002-09-21 | Senju Pharma Co | Aqueous suspension for nasal administration |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
US5830490A (en) | 1997-04-04 | 1998-11-03 | Weinstein; Robert E. | Method and device for organizing and coordinating the combined use of topical aerosols and oral medications for the treatment of disorders |
IL131492A0 (en) * | 1997-04-30 | 2001-01-28 | Warner Lambert Co | Topical nasal antiinflammatory compositions |
ES2215310T3 (es) | 1997-06-30 | 2004-10-01 | Glaxo Group Limited | Procedimiento para identificar compuestos que tienen una actividad sistemica reducida. |
EP0903151A1 (en) | 1997-09-22 | 1999-03-24 | ASTA Medica Aktiengesellschaft | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms |
US5972327A (en) | 1997-10-22 | 1999-10-26 | Lin; Matthew M. | Method of treating allergic rhinitis by delivering medication via the nasal vestibules |
SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
SE9704833D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New formulation |
US5972920A (en) | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
FR2779841B1 (fr) | 1998-06-15 | 2006-08-04 | Peugeot | Procede et dispositif de commande d'un actionneur electrique d'activation d'un systeme fonctionnel |
US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US6319513B1 (en) | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
US6136294C1 (en) | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
SE9803770D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Dry powder pharmaceutical formulation |
US6261539B1 (en) | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
US6294153B1 (en) * | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
GB9828721D0 (en) | 1998-12-24 | 1999-02-17 | Glaxo Group Ltd | Novel apparatus and process |
EP1020233A1 (en) | 1999-01-13 | 2000-07-19 | The Procter & Gamble Company | Dosing and delivering system |
GB9903759D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
WO2000049993A2 (en) | 1999-02-24 | 2000-08-31 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
EA007483B1 (ru) | 1999-04-30 | 2006-10-27 | Пфайзер Продактс Инк. | Применение модулятора рецепторов глюкокортикоидов и агониста рецепторов глюкокортикоидов при получении лекарственного средства |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20020061281A1 (en) | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US20020081266A1 (en) | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
WO2001020331A1 (en) | 1999-09-14 | 2001-03-22 | Xenoport, Inc. | Substrates and screening methods for transport proteins |
DE19947234A1 (de) * | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und Antihistaminika |
US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
IL150929A0 (en) | 2000-01-28 | 2003-06-24 | Rohm & Haas | Pharmaceutical compounds comprising a pharmaceutically active moiety and a moiety comprising a substituent that enhances its properties |
DK1252157T3 (da) | 2000-01-31 | 2004-10-25 | Pfizer Prod Inc | Pyrimidin-carboxamider anvendelige som inhibitorer af PDE4 isozymer |
US6565832B1 (en) | 2000-01-31 | 2003-05-20 | Schering-Plough Healthcare Products, Inc. | Spray composition with reduced dripping |
DE10007203A1 (de) | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
US20020133032A1 (en) | 2000-02-25 | 2002-09-19 | Jufang Barkalow | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods |
GB0009592D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
GB0009591D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical combinations |
GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
GB0009606D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
GB0016040D0 (en) | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
GB0017988D0 (en) | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Novel process |
EP1318787A2 (en) | 2000-07-26 | 2003-06-18 | Alcon Inc. | Pharmaceutical suspension compositions lacking a polymeric suspending agent |
CA2417973A1 (en) | 2000-08-04 | 2002-02-14 | Longwood Pharmaceutical Research, Inc. | Formulations of mometasone and a bronchodilator for pulmonary administration |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
EA005992B1 (ru) | 2000-08-05 | 2005-08-25 | Глаксо Груп Лимитед | S-ФТОРМЕТИЛОВЫЙ ЭФИР 6α,9α-ДИФТОР-17α-[(2-ФУРАНИЛКАРБОНИЛ)ОКСИ]-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОКИСЛОТЫ В КАЧЕСТВЕ ПРОТИВОВОСПАЛИТЕЛЬНОГО АГЕНТА |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
JP2002053485A (ja) | 2000-08-08 | 2002-02-19 | Oshida Tetsuo | アレルギー性疾患用医薬組成物 |
AR032362A1 (es) | 2000-08-14 | 2003-11-05 | Glaxo Group Ltd | Formulacion topica estable de una emulsion de aceite en agua y proceso para su preparacion |
US7157457B2 (en) | 2000-09-29 | 2007-01-02 | Glaxo Group Limited | Compounds useful in the treatment of inflammatory diseases |
ZA200108461B (en) | 2000-10-27 | 2002-06-06 | Celanese Chem Europe Gmbh | Process of telomerizing conjugated dienes. |
IL155676A0 (en) | 2000-10-31 | 2003-11-23 | Boehringer Ingelheim Pharma | Inhalative solution formulation containing a tiotropium salt |
EP1333830A2 (de) | 2000-10-31 | 2003-08-13 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden |
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
TWI290145B (en) | 2000-12-22 | 2007-11-21 | Nippon Shinyaku Co Ltd | Preventives/remedies for inflammatory airway diseases |
US20020132803A1 (en) | 2001-01-05 | 2002-09-19 | Mahendra Dedhiya | Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus |
US6583180B2 (en) * | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
GB0105560D0 (en) | 2001-03-07 | 2001-04-25 | Glaxo Group Ltd | Pharmaceutical formulations |
US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
US7045658B2 (en) | 2001-03-22 | 2006-05-16 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
AU2002303425A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
AU2002253342B2 (en) | 2001-04-30 | 2007-01-04 | Glaxo Group Limited | Novel anti-inflammatory androstane derivatives |
ES2307751T3 (es) | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
WO2003013427A2 (en) | 2001-08-03 | 2003-02-20 | Smithkline Beecham Corporation | A method for preparing fluticasone derivatives |
GB0124523D0 (en) | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
CA2464531A1 (en) | 2001-11-05 | 2003-05-15 | Brigham And Women's Hospital, Inc. | Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases |
WO2003042229A1 (en) | 2001-11-12 | 2003-05-22 | Glaxo Group Limited | Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids |
GB0127160D0 (en) | 2001-11-12 | 2002-01-02 | Glaxo Group Ltd | Novel compounds |
AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
ES2258175T3 (es) | 2001-12-05 | 2006-08-16 | Alcon, Inc. | Utilizacion de un antagonista de h1 y remixolona como esteroide inofensivo para el tratamiento de la rinitis. |
WO2003072592A1 (en) | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
WO2003062259A2 (en) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
DE60321311D1 (de) | 2002-02-04 | 2008-07-10 | Glaxo Group Ltd | Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten |
GB0202635D0 (en) | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
DE10216429A1 (de) | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
JP3691459B2 (ja) | 2002-06-14 | 2005-09-07 | 久光メディカル株式会社 | 粉末状吸入剤組成物 |
GB0217504D0 (en) | 2002-07-29 | 2002-09-04 | Novartis Ag | Organic compounds |
US7244742B2 (en) | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
PT1545548E (pt) * | 2002-08-30 | 2010-09-02 | Nycomed Gmbh | Utilização da combinação de ciclesonida e anti-histamínicos para o tratamento de rinite alérgica |
US20040235807A1 (en) | 2003-05-21 | 2004-11-25 | Weinrich Karl P. | Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
US20050192261A1 (en) | 2003-09-15 | 2005-09-01 | Jost-Price Edward R. | Methods and reagents for the treatment of immunoinflammatory disorders |
WO2005030331A1 (en) | 2003-09-26 | 2005-04-07 | Fairfield Clinical Trials, Llc | Combination antihistamine medication |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
DK2486942T3 (en) | 2004-11-24 | 2019-01-28 | Meda Pharmaceuticals Inc | COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT |
WO2006072599A2 (en) | 2005-01-10 | 2006-07-13 | Glaxo Group Limited | Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
GB0507165D0 (en) | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
WO2007061454A1 (en) | 2005-11-22 | 2007-05-31 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
GB0615108D0 (en) | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
AR073796A1 (es) * | 2008-10-10 | 2010-12-01 | Schering Corp | Formulaciones de corticosteroides y sus metodos de tratamiento |
-
2002
- 2002-06-14 GB GB0213739A patent/GB2389530B/en not_active Expired - Lifetime
-
2003
- 2003-06-13 AU AU2003244799A patent/AU2003244799B2/en not_active Ceased
- 2003-06-13 EP EP03738280A patent/EP1519731B1/en not_active Revoked
- 2003-06-13 DE DE60327203T patent/DE60327203D1/de not_active Expired - Lifetime
- 2003-06-13 CN CNA038191709A patent/CN1674910A/zh active Pending
- 2003-06-13 DK DK09075100.9T patent/DK2075000T3/da active
- 2003-06-13 PL PL03373001A patent/PL373001A1/xx unknown
- 2003-06-13 SI SI200331607T patent/SI1519731T1/sl unknown
- 2003-06-13 PT PT03738280T patent/PT1519731E/pt unknown
- 2003-06-13 ES ES09075100.9T patent/ES2545205T3/es not_active Expired - Lifetime
- 2003-06-13 NZ NZ574658A patent/NZ574658A/en not_active IP Right Cessation
- 2003-06-13 CA CA2779633A patent/CA2779633C/en not_active Expired - Fee Related
- 2003-06-13 PT PT90751017T patent/PT2072051E/pt unknown
- 2003-06-13 ES ES09075101.7T patent/ES2456822T3/es not_active Expired - Lifetime
- 2003-06-13 ES ES03738280T patent/ES2324910T3/es not_active Expired - Lifetime
- 2003-06-13 NZ NZ537246A patent/NZ537246A/en not_active IP Right Cessation
- 2003-06-13 RU RU2005100781A patent/RU2361593C3/ru active Protection Beyond IP Right Term
- 2003-06-13 KR KR1020117022533A patent/KR101301558B1/ko active IP Right Grant
- 2003-06-13 EP EP09075101.7A patent/EP2072051B1/en not_active Revoked
- 2003-06-13 AT AT03738280T patent/ATE428428T1/de active
- 2003-06-13 SI SI200332442T patent/SI2075000T1/sl unknown
- 2003-06-13 US US10/518,016 patent/US8168620B2/en active Active
- 2003-06-13 HU HUE09075100A patent/HUE027184T2/en unknown
- 2003-06-13 DK DK03738280T patent/DK1519731T3/da active
- 2003-06-13 MX MXPA04012666A patent/MXPA04012666A/es active IP Right Grant
- 2003-06-13 CA CA2489427A patent/CA2489427C/en not_active Expired - Lifetime
- 2003-06-13 KR KR1020117022532A patent/KR101301061B1/ko active IP Right Review Request
- 2003-06-13 CA CA2779630A patent/CA2779630C/en not_active Expired - Fee Related
- 2003-06-13 AP AP2004003192A patent/AP2004003192A0/xx unknown
- 2003-06-13 SI SI200332345T patent/SI2072051T1/sl unknown
- 2003-06-13 EP EP09075100.9A patent/EP2075000B1/en not_active Revoked
- 2003-06-13 DK DK09075101.7T patent/DK2072051T3/da active
- 2003-06-13 KR KR1020047020819A patent/KR101119895B1/ko active IP Right Grant
- 2003-06-13 WO PCT/GB2003/002557 patent/WO2003105856A1/en active Application Filing
- 2003-06-13 BR BRPI0312128A patent/BRPI0312128B8/pt active IP Right Grant
- 2003-06-13 PT PT90751009T patent/PT2075000E/pt unknown
-
2004
- 2004-12-14 IL IL165771A patent/IL165771A/en active IP Right Grant
- 2004-12-14 TN TNP2004000247A patent/TNSN04247A1/en unknown
-
2005
- 2005-01-13 MA MA28040A patent/MA27285A1/fr unknown
- 2005-01-13 ZA ZA200500331A patent/ZA200500331B/en unknown
- 2005-01-14 CR CR7654A patent/CR7654A/es not_active Application Discontinuation
-
2009
- 2009-06-30 CY CY20091100686T patent/CY1109196T1/el unknown
- 2009-07-23 US US12/508,388 patent/US8318709B2/en not_active Expired - Fee Related
- 2009-07-23 US US12/508,393 patent/US8304405B2/en not_active Expired - Fee Related
- 2009-11-30 AU AU2009243422A patent/AU2009243422C1/en not_active Ceased
- 2009-11-30 AU AU2009243420A patent/AU2009243420B2/en not_active Ceased
-
2010
- 2010-07-12 GE GEAP201011799A patent/GEP20115143B/en unknown
- 2010-09-10 US US12/879,515 patent/US8163723B2/en not_active Expired - Lifetime
-
2011
- 2011-12-13 IL IL216931A patent/IL216931A/en active IP Right Grant
- 2011-12-13 IL IL216932A patent/IL216932A/en active IP Right Grant
-
2012
- 2012-10-03 US US13/644,127 patent/US8937057B2/en not_active Expired - Lifetime
- 2012-10-03 US US13/644,126 patent/US8933060B2/en not_active Expired - Lifetime
-
2013
- 2013-07-10 HU HUS1300032C patent/HUS1300032I1/hu unknown
- 2013-08-22 LU LU92269C patent/LU92269I2/fr unknown
-
2014
- 2014-01-15 CY CY2014001C patent/CY2014001I1/el unknown
- 2014-02-20 CY CY20141100132T patent/CY1115386T1/el unknown
- 2014-11-12 US US14/539,646 patent/US20150072010A1/en not_active Abandoned
-
2015
- 2015-03-18 US US14/661,700 patent/US20150224116A1/en not_active Abandoned
- 2015-03-18 US US14/661,720 patent/US9259428B2/en not_active Expired - Fee Related
- 2015-09-16 CY CY20151100813T patent/CY1116693T1/el unknown
-
2016
- 2016-03-15 US US15/070,839 patent/US9901585B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005100781A (ru) | Комбинация азеластина и стероидов | |
US11191838B2 (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
ES2626134T3 (es) | Composiciones de bepotastina | |
ES2332290T3 (es) | Formulaciones farmaceuticas que comprenden un agonista de beta2 de accion prolongada para su administracion mediante nebulizacion. | |
AU2003291497B2 (en) | The use of an anti-allergy agent and a steroid to treat allergic rhinitis | |
JP5524438B2 (ja) | ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物 | |
JP2009544665A (ja) | 炎症病態またはアレルギー病態を治療するための、アゼラスチンとコルチコステロイドとを含む医薬製剤 | |
CN110237031B (zh) | 包含释放一氧化氮的前列酰胺的眼用组合物 | |
JP2014515360A (ja) | フルチカゾンを含む鼻用医薬製剤 | |
AU2021254650B2 (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
WO2022007743A1 (zh) | 粘膜给药剂型和其应用 | |
WO2005053672A1 (ja) | シロミラストまたはその塩を有効成分とする掻痒治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ND4A | Extension of patent duration |
Effective date: 20220404 |